In addition to selecting molecules of pharmacological interest, high-throughput screening campaigns often generate hits of undesirable mechanism, which cannot be exploited for drug discovery as they lead to obvious problems of specificity and developability. Examples of undesirable mechanisms are target alkylation/acylation and compound aggregation. Both types of "promiscuous" mechanisms have been described in the literature, as have methods for their detection. In addition to these mechanisms, compounds can also inhibit by oxidizing susceptible enzyme targets, such as metalloenzymes and cysteine-using enzymes. However, this redox phenomenon has been documented infrequently, and an easy method for detecting this behavior is missing. In this article, the authors describe direct proof of small-molecule oxidation of a cysteine protease by liquid chromatography/tandem mass spectrometry, develop a simple assay to predict this oxidizing behavior by compounds, and show the utility of this assay by demonstrating its ability to distinguish nuisance redox compounds from well-behaved inhibitors in 3 historical GlaxoSmithKline drug discovery efforts. (Journal of Biomolecular Screening 2007:881-890) 
INTRODUCTION
T HE SUCCESSFUL DECONVOLUTION of a high-throughput screening (HTS) campaign often involves identifying what hits are undesirable to confidently progress hits of value. This is because multiple mechanisms exist in which small molecules can appear as positives in a screen, yet the mechanism by which they show up as hits is of no value for drug discovery. These include obvious and easy to test technology-dependent phenomena, such as auto-fluorescence and fluorescence quenching, as well as more complex and less understood biophysical/chemical mechanisms, such as compound alkylation/acylation, compound aggregation, and compound redox reactivity. 1, 2 Compounds that inhibit because they chemically react with the target protein can be detected through techniques such as ALARM NMR (a La assay to detect reactive molecules by nuclear magnetic resonance) or jump dilutions. In an ALARM NMR experiment, a test compound is mixed with a 224-amino acid portion of the human La protein, and resulting shift changes and line broadening in the 13 C NMR spectrum of La are observed upon modification of specific residues. 3 In a typical jump dilution experiment, an inhibitor is preincubated at > 10× IC 50 with the protein of interest and then rapidly diluted > 100-fold into a reaction containing substrate. Reversible compounds upon dilution below IC 50 display a return of enzymatic activity, whereas reactive compounds do not. 4 The phenomenon of compound aggregation was recently described for the first time in 2002 by McGovern and coworkers. 5 Although the biophysical nature of the compound aggregates is still poorly understood, intensive efforts in both industry and academia in the past 5 years have resulted in several excellent articles chronicling this effect, as well as methods to detect it. [6] [7] [8] In contrast to these nuisance mechanisms, the phenomenon whereby compounds exert their apparent activity through target oxidation has been far less studied. Redox modification of enzymes in vivo is a well-established mechanism for posttranslational control of enzyme activity. 9, 10 Although this allows careful regulation in the cellular environment, it creates a challenge for drug discovery efforts with these targets, as compound-mediated oxidation is not considered an exploitable mechanism of action (MOA) for drug development. Small-molecule-mediated oxidation of targets in vitro has been documented only occasionally, 11, 12 and importantly, an understanding of this mechanism as well as a method for their detection is lacking.
To avoid progression of this type of HTS hits, we describe herein the development of a simple surrogate assay that detects the propensity of compounds to oxidize targets and provide a plausible mechanism as a basis for understanding its scope and limitations. In addition, compounds from 3 historical HTS campaigns of enzyme targets at GlaxoSmithKline (GSK) are examined to demonstrate the utility of this assay.
MATERIALS AND METHODS

Materials
Resazurin (cat. R12204) and resorufin (cat. R363) were purchased from Invitrogen (Carlsbad, CA). Dithiothreitol (DTT; cat. D9779), reduced L-glutathione (cat. G6529), N-acetyl cysteine (cat. A9165), catalase (cat. C40), and superoxide dismutase (SOD; cat. S8409) were purchased from Sigma (St. Louis, MO). Z-VAD-FMK, methyl ester (cat. P416) was purchased from Biomol Research Labs (Plymouth Meeting, PA).
Methods
CatL IC 50 determinations. Compounds (100 nL) were stamped into black low-volume 384-well Greiner plates using a Hummingbird (Genomic Solutions, Ann Arbor, MI). The buffer used in these experiments was 100 mM sodium acetate, 5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM CHAPS, and 1 mM DTT, pH 5.5. Cathepsin L (CatL) was diluted to 30 pM in buffer, and 5 µL of this solution was added to all wells of the plate using a multidrop micro (Thermo, Waltham, MA). The wells were allowed to react for 60 min. Substrate z-L-R-AMC (cat. AMC-053, MP Biomedicals, Solon, OH) was diluted to 4 µM in buffer, and 5 µL of this solution was added to all wells of the plate using a multidrop micro. The wells were allowed to react for 60 min and were subsequently read on an Acquest (Molecular Devices, Sunnyvale, CA) with Ex = 360 nm/Em = 460 nm using a 400-nM cutoff filter.
LC/MS/MS detection of redox modification in intact and
digested CatL. Intact protein analysis was performed by online reversed-phase high-performance liquid chromatography (RP-HPLC) electrospray orthogonal acceleration time-of-flight mass spectrometry (ESI-oa TOF MS) analysis on an LCT (Micromass, Manchester, UK). An HP1100 HPLC (Agilent Technologies, Santa Clara, CA) was interfaced with the LCT, and protein samples were desalted on a Poros R1/10 2.1 × 100-mm column using a 3-min linear gradient of 16% to 64% acetonitrile in water containing 0.1% trifluoroacetic acid (TFA) using a thermostatcontrolled column heater maintained at 60 °C. Samples were introduced into the mass spectrometer using a 1:4 flow-split postcolumn. The MS source interface parameters were set as follows: capillary 3000 V, sample cone 30 V, rf lens 500 V, extraction cone 5 V, desolvation gas 600 L/h, desolvation temperature 300 °C, and source temperature 100 °C. Molecular masses of intact protein species were obtained through deconvolution of raw data charge envelopes by iterating to convergence using MaxEnt 1 software (Micromass).
For determination of cysteinyl active site modification, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed, and purified gel bands were reduced, alkylated with iodoacetamide, and digested overnight with chymotrypsin at 1:20 w/w enzyme/substrate. Extracted peptide digests were analyzed by data-dependent liquid chromatography electrospray tandem mass spectrometry (LC/ES MS/MS) on an LC-MSD Trap XCT Ultra ion trap (Agilent Technologies). Peptide samples were loaded on a Chip Cube containing a 4-mm, 40-nL enrichment cartridge and backflushed onto a 43-mm × 75-µm i.d. Zorbax 300SB-C18 analytical column at 300 nL/min using a 7-min linear gradient of 4% to 28% acetonitrile in water containing 0.1% formic acid. MS survey scans and MS/MS product ion scans were recorded in a data-dependent manner as follows: Redox assay for compound profiling. Compounds (100 nL) were stamped into a black, low-volume Greiner plate using a Hummingbird (Genomic Solutions). Resazurin was added to buffer (50 mM HEPES, 50 mM NaCl, pH 7.5) at a final concentration of 5 µM, and DTT was added at a final concentration of 50 µM. Then, 10 µL of this solution was added to all wells of the assay plate using a multidrop micro (Thermo). The wells were allowed to react for 60 min at room temperature after addition of the resazurin/DTT solution and were then read on a Viewlux (PerkinElmer, Waltham, MA) with Ex = 560 nm/Em = 590 nm. pH profile determination. The standard redox assay was performed as described above but in the following buffers, all at 50 mM and with 50 mM NaCl: pH 4.75 sodium citrate, pH 5.5 MES, pH 6.0 MES, pH 6.5 MES, pH 7.0 HEPES, pH 7.5 HEPES, pH 8.0 HEPES, pH 8.5 TAPS, pH 9.0 TAPS, and pH 10.0 TAPS. In a separate experiment, resorufin itself was also added at 1 µM final concentration to each of the buffers to account for pH effects on resorufin fluorescence.
RESULTS AND DISCUSSION
Determination that compound inhibition is through protein oxidation
Inhibitors with structures such as compounds 1 to 3 ( Fig. 1) have been discovered as hits in many HTS campaigns at GSK. Several of the inhibited targets are cysteine proteases, enzymes with essential active site cysteines, or metal-using proteins. Based on the pattern of effected targets and the literature precedent for some of these targets to be oxidatively modified, [9] [10] [11] [12] [13] [14] we sought to better define their mode of inhibition. Thus, inhibition of CatL by several analogs of this series (compounds 1-3) was examined more closely. CatL is a cysteine protease and is commonly run as a selectivity assay for programs as it represents a known liability. 15 After determining that all 3 analogs were potent inhibitors of CatL (IC 50 = 30 nM, 10 nM, and 23 nM for compounds 1-3, respectively), the protein itself was examined by LC/MS after treatment with either compounds 1 to 3 or DMSO as a control. CatL samples treated with all 3 analogs displayed increases of both 32 and 48 mass units ( Fig. 2a ) compared with the control sample ( Fig. 2b) , consistent with oxidation of the catalytic cysteine to the sulfinic and sulfonic oxidation states, respectively. Note the protein is expressed as a 403-amino acid prepro-form in Chinese hamster ovary (CHO) cells, purified as a secreted Fc fusion from conditioned media, and autoactivated. Endo-H treatment suggests that the protein contains homogeneous N-linked glycosylation, although the C-terminus of the autoactivated protein has not been experimentally confirmed; as such, it is not possible to compare experimental data to a theoretical mass for the unmodified intact protein.
To further localize oxidation to the sulfhydryl group of the active site cysteine residue, the protein was digested with chymotrypsin, and the resulting peptides were analyzed by LC/MS/MS. Enzymatic treatment of intact proteins is used to create peptides of the preferred mass range for mass spectrometrybased sequencing, resulting in information-rich, easily interpretable peptide fragmentation spectra. In an MS/MS experiment, a particular peptide "precursor ion" is isolated, energy is imparted by collisions with an inert gas, and this energy causes the peptide to fragment into product ions. The most common and informative ions are generated by fragmentation at the amide bond between amino acids; the resulting ions are called b-ions if the charge is presence of the y 2 ion at m/z 365.1 Da and the y 5 ion at m/z 669.3 Da indicates carboxyamidomethylation of both cysteine residues ( Fig. 3a) . These modifications are present as a consequence of sample workup to irreversibly alkylate free sulfhydryl groups prior to enzymatic digestion. Because this chemistry occurs postincubation with compounds, these data are consistent with no oxidation of the active site. In contrast, Cathepsin L protein inhibited with compound 1 exhibited a substantial reduction of the m/z 810.9 Da precursor and production of a major new doubly charged peak of m/z 806.3 Da. LC/MS/MS analysis of this precursor confirmed modification of the peptide to the sulfonic oxidation state (Fig. 3b) . Furthermore, positive assignment of the b 10 (m/z 1112.7) and b 13 (m/z 1407.7) ions conclusively localized modification to the Cys13 active site residue rather than Cys10, which was observed solely as the carboxamidomethylated form. Sulfinic acid modification of the active site producing a minor precursor ion at m/z 798.3 Da was also observed (data not shown). Collectively, these data conclusively support irreversible oxidation of the CatL active site cysteine residue by compounds 1 to 3.
Development of a surrogate assay to measure compound oxidation
Although the MOA of these compounds was solved by LC/MS/MS techniques, we still desired a higher throughput, plate-based assay to enable efficient triage of the thousands of hits typically generated from an HTS campaign. As with many discoveries, the development of our oxidation detection assay was based partially on serendipity. In a historical effort aimed at finding activators of glucokinase (a target for obesity 17 ), we developed an activity assay, which coupled glucose-6-phosphate production to resorufin through glucose-6-phosphate dehydrogenase (G6PDH) and diaphorase ( Fig. 4) . After running the HTS, it was found that the vast majority of the hits (2203 out of 2262) were unable to be confirmed running the glucokinase assay in absorbance mode, monitoring nicotinamide adenine dinucleotide (NADH) production ( Fig. 4) . Upon closer examination, we found that the 2203 compounds (considered nuisance hits) were able to produce resorufin from resazurin in the absence of glucokinase; only compound, resazurin, and DTT were required for reaction.
Based on the fact that inhibitors with structures such as compounds 1 to 3 were well represented among the nuisance hits from the glucokinase HTS, as well as our LC/MS/MS results that these compounds can oxidize (and thus inhibit) the active Coupled enzyme assay for glucokinase. Glucokinase (GKase) activity is measured by converting glucose-6-phosphate to the gluconolactone, concomitant with reduction of NAD to NADH (absorbance format). NADH is then used by diaphorase to reduce resazurin to resorufin (fluorescence format). ATP, adenosine triphosphate; ADP, adenosine disphosphate; NAD/NADH, nicotinamide adenine dinucleotide. site cysteine of CatL, we thought the resazurin-to-resorufin redox reaction observed in the presence of DTT and compound might serve as a useful surrogate assay for measuring potential compound redox liability, after the mechanism was understood.
We first investigated the stoichiometry of the reaction. Interestingly, titration of the various components revealed that the amount of product (resorufin) produced is limited by the amount of resazurin and DTT added but not by compound. In fact, adding submicromolar amounts of compound 1 can produce as much as a 100-fold excess of resorufin ( Fig. 5) . From these results, we conclude that the compound is acting as a catalyst, facilitating the net 2ereduction of resazurin by DTT.
The effects of adding catalase and SOD to the reaction were examined next. Catalase catalyzes the disproportionation of H 2 are involved in the reduction of resazurin to resorufin in our assay, we would expect the addition of these enzymes to significantly reduce the observed signal when added with reactive compounds. The addition of either singly or in combination had little effect on the observed reaction with compound 1. Thus, it appears that the reduction of resazurin is not mediated by these ROS.
It should be noted that this assay is only a surrogate for measuring the ability of compounds to oxidize susceptible targets. Indeed, in the HTS assays for several of our susceptible targets, DTT is not present. Thus, although ROS are not responsible for the reduction of resazurin in our assay, species such as H 2 O 2 or O 2 can be formed when these compounds are mixed with thiols in solution 18 and may mediate the reaction of redox compounds with a given drug target. This has been precedented for caspase-8, a cysteine protease. 11 Consistent with this idea, we found that a significant proportion of DTT (~60%-70%) is unaccounted for when it is the limiting reagent, which may be the result of a side reaction with O 2 . To examine this possibility, DTT was mixed with cytochrome C in the absence of compound, in the presence of compound 1, or in the presence of compound 1 plus SOD (Fig. 6) . Cytochrome C is commonly used for the chromogenic detection of O 2 -. 19 From Figure 6 , it can clearly be seen that the addition of compound to a solution of DTT produces O 2 -, which can be quenched when SOD is added.
The finding that superoxide is formed as a side reaction in the reduction of resazurin by DTT is suggestive that a DTT radical species is involved in the mechanism of this assay, initiated by the 1ereduction of the compound. This is consistent with what is known from the literature and led us to propose the following mechanism for the reaction (Fig. 7) . Initially, an electron is transferred from DTT to compound, resulting in a radical species similar to that observed with flavin biochemistry. 20 The next step likely involves the reaction of the DTT radical with resazurin. Reactions of resazurin with thiyl radicals are precedented 21 and occur at near-diffusion controlled rates. In the final step, compound is regenerated through the second 1ereduction of resazurin, producing resorufin. Although it is acknowledged that radical mechanisms are inevitably more divergent and complicated in reality, this minimalistic proposal accounts for all observed results and is thus a useful model to understand what type of compounds are likely to be detected in this assay. Based on this mechanism, several classes of enzymes are expected to be susceptible to oxidation. The mechanism for the nonheme, mononuclear, α-ketoglutarate-using enzymes 22 is shown in Figure 8a , where inhibition (boxed) results from oxidation of the iron from the active Fe(II) to the inactive Fe(III) species. Other Fe, Co, or Mn enzymes as well as enzymes using redox cofactors (such as flavins, pterins, quinones, etc.) may be susceptible to this type of inhibition.
Assay for Measuring Compound Redox Behavior
Enzymes with catalytically required cysteine residues are also susceptible to inhibition through oxidation. The mechanism for a prototypical cysteine protease is shown in Figure 8b ; 23 upon oxidation of the cysteine to the sulfenic, sulfinic, or sulfonic acid (boxed), enzymes will become inactive. Besides cysteine proteases, other enzymes that use cysteine as a nucleophile (phosphatases), as a general acid or base (such as isocitrate lyase), or for required structural motifs (such as Zn finger domains) would also be susceptible.
Given the desire to avoid "discovering" these compounds in an HTS campaign, an understanding of how to mediate this redox activity would be useful for HTS design. Increasing ionic strength in our detection assay through the addition of NaCl and KCl had no effect. Divalent metals such as Ca 2+ and Mg 2+ similarly had no effect; however, Mn 2+ (which can undergo 1ereduction itself) enhanced the observed reaction, presumably acting as an alternate catalyst. Bovine serum albumin (BSA) and CHAPS, which are typically added to assays to mediate nonspecific protein and hydrophobic effects, respectively, also had no effect. Adding in other thiol-containing compounds, such as glutathione or N-acetyl cysteine (NAcCys), was also examined in the hope that these reagents might provide alternative reducing equivalents to act as "redox buffers." However, adding in either glutathione or NAcCys up to 10 mM had no effect on the reaction of compound 1 with the resazurin/DTT mixture.
Changing the buffer at a constant pH from HEPES to Tris or phosphate also did not affect the reaction. The reaction was greatest at neutral pH ( Fig. 9, open circles) and appeared to fall off rapidly at lower values; however, reactions at pH values lower than 6.0 could not be confidently interpreted due to pH effects on resorufin fluorescence ( Fig. 9, closed circles) . Even though we were not able to find a simple way to reduce the reactivity of oxidizing compounds, a secondary assay to screen out redox behavior can easily be configured using the resazurin-to-resorufin reaction described above. We typically make a single solution containing 50 µM DTT and 5 µM resazurin and add 10 µL to a plate containing the test compounds. After allowing 60 min for reaction, fluorescence intensity is measured (Ex = 560 nm/Em = 590 nm).
As a side note, we had previously investigated (unsuccessfully) other assays for detection of redox compound behavior, based on the idea of detecting decreases in DTT concentration when mixed with compound. In light of the mechanism described here, it makes sense why those efforts failed; they relied on a stoichiometric reaction between DTT and compound for detection and thus were relatively insensitive to this behavior.
Testing of inhibitors from historical GSK targets
To further validate the utility of this assay, both classical inhibitors and suspect redox compounds from several historical GSK screening campaigns were evaluated. Caspase-8 is a cysteine protease involved in apoptotic signaling pathways. of the hits from an HTS against this target were reported to be due to compound-mediated oxidation, 11 including compounds 4 and 5 (Fig. 1) . These compounds as well as Z-VAD-FMK-OMe (a nonredox, pan caspase peptide inhibitor; pIC 50 = 6.0 against CatL) were evaluated in our assay. Although the suspect compounds displayed clear reactivity, Z-VAD-FMK-OMe did not (Fig. 10a) .
Next, compounds from a PTP-1B effort were reinvestigated. PTP-1B is a cysteine phosphatase involved in insulin signaling, and it has been shown that the active site cysteine may be modified via oxidation. 24, 25 Compounds discovered from our internal effort (compounds 6, 7, 8; structures not shown) that displayed nonclassical inhibition (irreversible, high Hill slopes; noncompetitive inhibition) were evaluated, along with a competitive, well-behaved peptidomimetic inhibitor (compound 9) described by Pharmacia. 26 Again, the known inhibitor was not detected in our assay, whereas the HTS hits were efficiently identified (Fig. 10b) as oxidative nuisance compounds.
Finally, hits against TauD were evaluated. TauD is a bacterial enzyme needed for metabolic sulfur acquisition 22 a class of mononuclear, nonheme iron-using enzymes. Again, suspect redox compounds 10 and 11 gave clear responses, whereas a known general inhibitor 27 of this class of enzymes (compound 12) did not (Fig. 10c) .
An interesting feature of the compound evaluations is that a full signal is not achieved for all compounds (for example, compound 8 in Fig. 10b ). This may reflect trapping out of some of the radical species by compound competitively with resazurin, resulting in bell-shaped plots for several of the inhibitors studied. Thus, careful scrutiny may be needed when reviewing compound profiling data.
Given the fact that redox reactive compounds were discovered during screening campaigns against these susceptible targets, we were curious as to the general occurrence in a random sample population. At GSK, new assays are typically tested against a validation set of ~10,000 wells (28 × 384 plates), representing a diverse set of compounds; we screened the validation set in our assay as single shots at 10 µM, a typical concentration used in HTS campaigns. DMSO was used for negative control wells and 1 µM compound 1 for positive control wells. Given that program compounds demonstrated responses that did not reach 100% conversion of resazurin to resorufin, we selected a response of > 5-fold over background (typically corresponding to > 25% maximum response) for the definition of a hit. It is important to note that this cutoff was greater than 30 times the standard deviation over the negative controls for all plates. The overall hit rate was 2.3% for compound samples, and the assay performance was consistently good (average Z′ = 0.78) (Fig. 11) . This hit rate may be viewed in a positive light in that a minority of GSK compounds appears to carry this liability; however, for an HTS of 1 million compounds against a susceptible target, this would correspond to 23,000 undesirable hits. Given these results, the redox assay described herein is expected to be most useful in the context of post-HTS secondary screening for targets susceptible to oxidation.
SUMMARY
This work describes a facile, high-throughput assay that can be used to profile HTS hits for their tendency to undergo redox chemistry. For 3 targets, we demonstrated the ability of this assay to discern the redox compounds from well-behaved inhibitors. Thus, pharmaceutical targets that perform redox chemistry (e.g., oxidases and hydroxylases) or targets with functional groups susceptible to redox modification (e.g., cysteine proteases and phoshatases) would likely benefit from analysis with this assay. 
